FP01

Avalo Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	FP01
Sponsor	Avalo Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough (PHASE2)
Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection (PHASE2)
A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FP01 CI brief — competitive landscape report
FP01 updates RSS · CI watch RSS
Avalo Therapeutics, Inc. portfolio CI